Nexalin Technology Inc. has announced the publication of additional positive clinical data for its Gen-2 SYNC 40-Hz Deep Intracranial Frequency Stimulation (DIFS™) device in the treatment of mild Alzheimer's disease. The results, already published in Radiology, the flagship journal of the Radiological Society of North America (RSNA), indicate that the device significantly improves cognitive performance and enhances brain network connectivity. The randomized, sham-controlled trial found clinically meaningful gains in Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores compared to baseline and to the sham group. Resting-state functional MRI demonstrated enhanced connectivity between the hippocampus and key cortical regions. No adverse events were reported during the treatment period.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9542003-en) on October 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.